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cense.Abstract Background: Kaposi’s sarcoma (KS) is an angioproliferative disorder associated with
human herpesvirus 8 infection. Classic KS is the most prevalent type of KS in countries of the Med-
iterranean basin including Egypt. Several in vitro studies have detected c-kit expression in AIDS
related-KS however, only a few studies addressed this issue in the classic type with no data on
the ethnicity of studied cases. The prospect of installing targeted anti- c-kit treatment to KS patients
presents a promising avenue in KS therapeutics.
Aim: To elucidate the expression of c-kit in classic KS cases and study possible relations with
expression of HHV8 latency-associated nuclear antigen-1 (LANA-1) and other clinicopathological
parameters.
Methods: Twenty four cases of classic KS of the plaque and nodular stages in the lower limb were
studied. Immunohistochemical detection of HHV8-LANA-1 and c-kit was carried out on archival
parafﬁn embedded tissue, possession of the Pathology and Dermatology Departments, Alexandria
School Of Medicine, Egypt. Statistical analysis of possible relations between both antigens and clin-
icopathological parameters (patient’s age and gender and histological stage) was performed.g EL Ryadah [A], Acid City,
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1 KS: Kaposi sarcoma.
2 HHV8: Human Herpes Virus.
3 LANA-1: Latency-Associated Nucle
2 T.M. Hussein et al.Results: HHV8 expression was detected in 100% of cases while c-kit immunoreactivity was found
in 54.2% of cases. There was no correlation between c-kit and HHV8 immunoreactivity or any of
the studied clinicopathological parameters.
Conclusions: This is the ﬁrst report of c-kit expression in classic KS in an ethnically homogeneous
cohort of Arabs of the Mediterranean region. We detected c-kit expression in about half the cases
with no relationship to HHV8 LANA expression or clinicopathological parameters.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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Kaposi’s sarcoma (KS1), ﬁrst described in 1872, is an angio-
proliferative disorder associated with infection with human
herpesvirus 8 (HHV8) [1]. It is classiﬁed into four clinico-epi-
demiological types: classic, endemic (African), iatrogenic
(post-transplantational) and AIDS-associated (epidemic) [2,3].
Classic KS typically presents in middle or old aged men of
Mediterranean, Eastern European and Jewish descent in
whom lesions usually occur on the distal extremities [2,4,5].
Clinically, classic KS presents with purplish skin patches,
plaques, and nodules which may ulcerate and bleed. Skin
lesions vary in size from minute to several centimeters in diam-
eter and can remain static for years or pursue a rapid course
within a few weeks [6].
Histopathologically, the earliest lesion, the ‘patch’ stage
features thin-walled vascular spaces in the upper dermis with
few mononuclear inﬂammatory cells [3]. Next, the ‘plaque’
stage presents increasing vascular spaces surrounded by spin-
dle-cell bundles. In the late ‘nodular’ stage, the tumor becomes
more solid with large fascicles of spindled cells and fewer vas-
cular spaces, inﬂammatory cells and entrapped extravasated
erythrocytes and macrophages [4,7].
In 1994, a novel human herpesvirus (HHV82), Kaposi’s
Sarcoma-associated Herpesvirus (KSHV), was found to be
present in almost 100% of KS lesions of all epidemiological
types, in multicentric Castleman’s disease and primary effusion
lymphoma [8,9].
The HHV8 viral genome comprises about a 140-kb long un-
ique region ﬂanked by multiple terminal repeat sequences [10].
The virus is difﬁcult to cultivate, therefore, diagnosis of infec-
tion rests on demonstration of antibodies to the virus or
detecting viral nucleic acid in clinical specimens. Proteins ex-
pressed by the virus depend on the stage of infection whether
latent or lytic [3,10,11].
During latency, three genes are expressed from the viral
episome; orf72, K13 (vFLIP) and orf73 (Latency-Associated
Nuclear Antigen, or LANA-13). LANA-1 is a nuclear phos-
phoprotein essential for HHV8 episomal maintenance and seg-
regation [10], and is a highly sensitive and speciﬁc marker of
Kaposi’s sarcoma [12]. The antigen has been shown to bind
and inactivate the tumor suppressor functions of the pRb
and p53 proteins and to immortalize endothelial cells [3,10].
In experimental studies involving HHV8-infected endothe-
lial cells, one of the most consistent virus-induced genes was
c-kit [13,14] which was found to be important in the transfor-
mation of endothelial cells [3] and imply that inhibition of thear Antigen-1.c-kit receptors may represent a promising target for pharmaco-
logical intervention [15].
C-kit is a transmembrane glycoprotein receptor (deﬁned by
the CD117 antigen) of the tyrosine kinase family encoded by
the c-kit proto-oncogene. C-kit is normally expressed on hema-
topoietic cells, endothelial cells, germ cells and melanocytes
[16]. Through its interactions with its ligand; stem cell factor,
c-kit mediates crucial cellular functions as cell proliferation,
intercellular adhesion and cellular spindling [14,16,17].
In the current work we employed several scoring systems to
fully explore c-kit expression in the classic variant of KS, the
type most prevalent in the Mediterranean city of Alexandria;
in relation to expression of HHV8 LAN antigen and other
clinicopathological parameters.
Material and methods
Patients and specimens
This retrospective study was approved by the Ethics Commit-
tee of Alexandria Faculty of Medicine. It consisted of 24 con-
secutive, clinically and histologically proven cases of classic,
cutaneous Kaposi’s sarcoma. Patients were diagnosed and
treated at the Alexandria Main University Hospital, Alexan-
dria, Egypt, between January 2002 and May 2010. All tissue
samples were formalin-ﬁxed and parafﬁn-embedded.
Cases with history of immunosuppressive therapy, organ
transplantation or HIV-1 infection were excluded.
Histopathological and immunohistochemical staining
Five micron-thick sections cut from archival parafﬁn blocks
were H&E stained and examined microscopically to determine
the histological stage.
Immunohistochemical studies were performed using the
streptavidin–biotin peroxidase system with Diaminobenzidine
as a chromogen. Heat-induced epitope retrieval was performed
by microwaving the samples for 30 min for HHV8 and 20 min
for c-kit at full power in 10 mmol/L sodium citrate buffer (pH
6.0).
Immunostaining for HHV8: was performed using the pri-
mary rat monoclonal antibody; HHV8 (LN53) (Santa Cruz
Biotechnology, Inc., CA, USA, Catalogue Number sc-73588)
at a 1:50 dilution incubated with tissue sections overnight at
4 C. The rat ABC Staining System detection kit (Santa Cruz
Biotechnology, Inc., CA, USA, Catalogue number sc-2019)
was used to develop the signal. The positive control consisted
of a lymph node involved by Castleman’s disease [18]. Labeling
for HHV8 was considered positive if the staining was granular
and exclusively nuclear within spindle and endothelial cells.
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tailed assigning a score 0: when no or <1% positive cells were
perceived, +1: 610% positive cells; +2, 10–50% positive cells
and +3: >50% positive cells [13].
Immunostaining for c-kit: was carried out using the primary
rabbit monoclonal anti-c-kit (CD117) antibody (prediluted
PATHWAY C-KIT (CD117), clone 9.7, Ventana Medical Sys-
tems, Inc., Tucson, AZ, USA, Catalogue Number 790-2951)
optimized for use on a Ventana automated slide stainer (The
BenchMark XT, Part Number N750-BMKXT-FS) whereby
tissue sections were incubated with the primary antibody for
32 min at 42 C, according to the manufacturer’s protocol.
Built in positive control was embodied in native mast cells
as well as basal keratinocytes [16,17].
Cytoplasmic and/or membranous staining reaction in >1%
of tumour cells was considered positive. Detailed assessment of
c-kit immunoreactivity entailed evaluation of c-kit percentage,
intensity and pattern of staining. The same scoring system ap-
plied for assessing HHV8 immunoreactivity was employed for
evaluation of c-kit percentage [13]. C-kit staining intensity was
scored as 1+ (weak), 2+ (moderate) and 3+ (strong) [13]. In
addition, c-kit staining pattern was assessed whether diffuse,
patchy (for clusters of cells) or focal (for individual cells) [17].
Negative control slides consisted of sections to which no
primary antibody was added.
Statistical analysis
Statistical analysis was done using SPSS for Windows software
(version 13.0; SPSS Inc., Chicago, IL, USA). Fisher exact test,
t test and Spearman rank correlation coefﬁcient were used for
statistical analysis. Signiﬁcance level was set at the 5% level.Figure 1 Plaque and nodular stages of KS and HHV8 immune expr
(H&E, X100), (C) Score +3, (D) Score +2 (C&D: Anti-HHV8 LANResults
In the current study, 24 cases were included. Fourteen were
males (58.3%) with a male: female ratio = 1.4:1. The mean
age (SD) was 59.79 (4.67) years ranging from 45 to 68 years.
All lesions were located in the lower limbs.
Histopathologically, there were no cases in the patch stage
while 8 (33.3%) were plaque stage and 16 (66.7%) were nodu-
lar stage tumours (Fig. 1A and B).
Immunostaining showed that positive, granular HHV8–
LANA-1 staining was detected in all cases in nuclei of spindle
cells and endothelial cells. A score 3+ staining reaction was
detected in 13 cases (54.2%) (Fig. 1C) while a score 2+ reac-
tion (Fig. 1D) was seen in 11 cases (45.8%). Reactivity was
conﬁned to lesional areas only.
C-kit immunoreactivity was detected in 13 cases (54.2%).
C-kit percentage was 3+ in 4 cases (30.8% of positive cases)
and 2+ in 9 cases (69.2% of positive cases). Intensity of the
staining reaction was 1+ in 5 cases (38.5% of positive cases)
and 2+ in 8 cases (61.5% of positive cases). C-kit staining pat-
tern was diffuse (Fig. 2A) in 8 cases (61.5% of positive cases)
and focal (Fig. 2C) in 5 cases (38.5% of positive cases).
Positive staining was seen in mast cells (Fig. 2B) and basal
keratinocytes (Fig. 2D) inﬁltrating KS lesions in all cases.
There was no signiﬁcant difference in the correlation be-
tween age distribution and immunoreactivity for HHV8
(Spearman rho = 0.29, P= 0.17). The same observation was
encountered with c-kit whereby there was no signiﬁcant corre-
lation between age distribution and overall c-kit immunoreac-
tivity (t= 1.07, P= 0.30), staining percentage (Spearman
rho: 0.20, P= 0.51), intensity (t= 0.02, P= 0.99) or pat-
tern of expression (t= 0.42, P= 0.68).ession. (A) Plaque stage-KS (H&E; X200), (B) Nodular-stage KS
A-1, X200).
Figure 2 C-kit cytoplasmic immune expression in KS. (A) Strong c-kit immunopositivity in dispersed mast cells (X400), (B) basal
keratinocytes expressing c-kit (x200), (C) diffuse, weak c-kit expression in nodular KS (x100), (D) focal, strong c-kit immunopositivity in
plaque-stage KS (x200).
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and either of HHV8 expression scores (P= 0.70) or c-kit
immunoreactivity whether overall positivity (P= 0.67), stain-
ing percentage (P= 1.00), intensity (P= 0.27) or pattern of
expression (P= 0.10).
There was no relation between HHV8 expression score and
histological stage of the tumour (P= 0.39) (Table 1). No statis-
tically signiﬁcant relation existed between stage and any of the
assessed c-kit parameters including overall reactivity, expression
percentage or intensity of staining (P= 1.00, 0.23 and 1.00,
respectively). A statistically signiﬁcant relation was found, how-
ever, between c-kit expression pattern and histological stage,
whereby diffuse immunoreactivity (in contrast to focal pattern)
was solely seen in the nodular stage (P= 0.007) (Table 1).
There was no statistically signiﬁcant relation between
expression of HHV8 and c-kit including overall reactivity, per-
cent, intensity or pattern (P= 0.44, 1.00, 0.27 and 1.00,
respectively) and other parameters (Table 2).
Discussion
In Egypt, where the classic type of KS clearly dominates over
all other epidemiological types, we studied the immune expres-
sion of c-kit in classic KS in relation to HHV8 expression and
some clinicopathological parameters. We employed several
scoring systems aiming at fully exploring this putative relation.
The invariable immunoreactivity for HHV8 [3,19] detected
in the present study was previously reported in KS [12,13,20].
Other authors [20,21] extrapolated that HHV8 LANA-1 detec-
tion could be used to distinguish Kaposi’s sarcoma from othervascular and nonvascular spindle cell lesions. However, lower
ﬁgures of antigen detection (78%) were reported [22] which
can be ascribed to the efﬁciency of epitope retrieval procedures
employed [21] and the multiplicity of epidemiological types
included in that study with their inherent differences in antigen
expression. This was detailed in the study by Pantanowitz et al.
[17] where HHV8 LANA-1 was detected in all cases of classic
KS, in 91% of AIDS-related and 60% of endemic cases.
In this work, as in others’ [22] no signiﬁcant difference was
found between HHV8 immunoreactivity scores and patients’
age or gender.
There was no correlation between HHV8 expression scores
and histological stage (P= 0.39) suggesting that progression
was not dependent on virus load.
In the present work, 54.2% of cases expressed c-kit.
Although a number of studies in the literature have scrutinized
c-kit expression in KS cases, their results exhibited notable
controversies [13,15,17,23,24]. Whereas some authors found
no expression [25], others detected the protein in 15.3% [24],
25.6% [26] or even in 43% of cases [17]. Kandemir et al. as-
cribe this stark contradiction to the fact the former two studies
[24,25] did not specify the exact epidemiological type or histo-
logical stage under study [13]. When we followed this debate, it
was clear that our ﬁgures were closest to those reported by
Pantanowitz et al. (56%) [17] in their work conducted exclu-
sively on classic KS. However, another research group [13]
working on classic KS could report a higher ﬁgure of c-kit
expression (62.9%) they explained the deviation in their results
with respect to others by the variation in technical parameters,
as length of storage and ﬁxation of tissues, the variation in
Table 1 Relation between tumor stage and each of HHHV8 and c-kit immunostaining scores.
Stage Total P value of
Fisher exact
Plaque Nodule
HHV8 Score 2 N 5 6 11 0.39
% 45.5% 54.5% 100.0%
Score 3 N 3 10 13
% 23.1% 76.9% 100.0%
C-kit expression Negative N 4 7 11 1.00
% 36.4% 63.6% 100.0%
Positive N 4 9 13
% 30.8% 69.2% 100.0%
C-kit percent Score 2+ N 4 5 9 0.23
% 44.4% 55.6% 100.0%
Score 3+ N 0 4 4
% 0 100.0% 100.0%
C-kit intensity +1 N 1 4 5 1.00
% 20.0% 80.0% 100.0%
+2 N 3 5 8
% 37.5% 62.5% 100.0%
C-kit pattern Focal N 4 1 5 0.007a
% 80.0% 20.0% 100.0%
Diﬀuse N 0 8 8
% 0% 100.0% 100.0%
a Statistically signiﬁcant at P 6 0.05.
Table 2 Relation between HHV8 and c-kit expression.
HHV8 Total P value of Fisher exact
Score +2 Score +3
C-kit expression Negative N 4 7 11 0.44
% 36.4% 63.6% 100.0%
Positive N 7 6 13
% 53.8% 46.2% 100.0%
C-kit percent Score 2+ N 5 4 9 1.00
% 55.6% 44.4% 100.0%
Score 3+ N 2 2 4
% 50.0% 50.0% 100.0%
C-kit intensity +1 N 4 1 5 0.27
% 80.0% 20.0% 100.0%
+2 N 3 5 8
% 37.5% 62.5% 100.0%
C-kit pattern Focal N 3 2 5 1.00
% 60.0% 40.0% 100.0%
Diﬀuse N 4 4 8
% 50.0% 50.0% 100.0%
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antibodies types) in addition to the possibility of sampling bias
[17].
Comparing our results regarding c-kit positivity in the dif-
ferent histological stages, to others’, reactivity in the plaque
cases (50%) was comparable to that obtained in the same stage
by Pantanowitz et al. (53%) [17]. However, our rates in the
nodular phase (56.2%) exceeded theirs (47%). It is worth not-
ing, however, that the latter study was conducted on epidemi-
ologically heterogeneous types of KS.In the current study, c-kit staining pattern was diffuse in
61.5% and focal in 38.5% of positive cases in a ﬁnding that
was reported before [17]. We can ascribe this to the fact that
two thirds of our cases belonged to the nodular stage which
proved to be signiﬁcantly related to the diffuse pattern of c-
kit immunopositivity.
No correlation was found between c-kit and HHV8 immu-
noreactivity. The same conclusion was reached previously
[13,17] which lead Kandemir et al. [13] to infer that LANA
expression is not directly under c-kit regulation.
6 T.M. Hussein et al.Several research groups demonstrated that inhibitors of
c-kit activation and signaling inhibited HHV8-associated pro-
liferation in culture [14–16]. Imatinib mesylate (Gleevec), a
selective inhibitor of tyrosine kinase used in the treatment of
gastrointestinal stromal tumor (GIST) [15,27] showed clinical
and histological regression in some cases of AIDS related KS
[3,27,28].
The tempting prospect of installing anti-c-kit treatment to
KS cases, that immunohistochemically express c-kit is now
standing on ﬁrm grounds and awaits clinical assessment. Our
work is the ﬁrst report of c-kit expression in cases of classic
KS in an Arab population in the Mediterranean basin. A study
from Turkey [13] addressed the same issue, however in an
ethnically different, non Arab cohort.
In conclusion, this is the ﬁrst report of c-kit expression in
classic KS in Egyptians; an ethnically homogeneous cohort of
Arabs of the Mediterranean region. We demonstrated expres-
sion of c-kit immunoreactivity in about half the studied cases.
No relationship was found between the immune expression of
c-kit and HHV8 LANA-1 or clinicopathological parameters.
Diffuse pattern of c-kit reactivity was signiﬁcantly related to
the nodular stage. Inhibiting c-kit activity might provide an
important therapeutic strategy for patients with classic KS.
The authors hereby declare the total absence of conﬂicting
or dual interests.
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